Analyst Research Report Snapshot

Title:

ACHILLION PHARMACEUTICALS - BACK IN THE HCV GAME

Price:

$10.00

Provider:

Edison Investment Research

Date:

18 Oct 2012

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ACHN.OQ

Available for Immediate Download
Summary:

With impressive single-dose ACH-3102 data, Achillion is back in the race to develop an all-oral, interferon (IFN)-free anti-HCV regimen. This would see its NS3 protease inhibitor, sovaprevir (ACH-1625), combined with ACH-3102, a NS5A inhibitor, with or without ribavirin (RBV). Achillion expects to initiate a Phase IIb trial of this combination in Q313; a Phase III trial starting in Q414 could, if successful, allow an NDA filing in Q216.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.